Celtic Pharmaceutical Development Services America

Celtic Pharmaceutical Development Services (CPDS) was the operational and clinical development arm of Celtic Pharmaceutical Holdings, a private equity firm focused on the biopharmaceutical sector. The company specialized in a virtual development model, where it acquired mid-to-late-stage drug candidates and managed their progression through Phase 3 clinical trials and regulatory approval using a network of contract providers. CPDS provided the strategic oversight and technical expertise necessary to advance assets such as Xerecept for brain edema and Colal-Pred for ulcerative colitis. By focusing on late-stage de-risked assets, the firm aimed to bridge the gap between initial proof-of-concept and commercial launch. Although a significant player in the mid-2000s, the company is no longer actively developing new programs as its primary investment funds have matured.